Literature DB >> 19665931

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.

Linda Douw1, Martin Klein, Selene Saa Fagel, Josje van den Heuvel, Martin Jb Taphoorn, Neil K Aaronson, Tjeerd J Postma, W Peter Vandertop, Jacob J Mooij, Rudolf H Boerman, Guus N Beute, Jasper D Sluimer, Ben J Slotman, Jaap C Reijneveld, Jan J Heimans.   

Abstract

BACKGROUND: Our previous study on cognitive functioning among 195 patients with low-grade glioma (LGG) a mean of 6 years after diagnosis suggested that the tumour itself, rather than the radiotherapy used to treat it, has the most deleterious effect on cognitive functioning; only high fraction dose radiotherapy (>2 Gy) resulted in significant added cognitive deterioration. The present study assesses the radiological and cognitive abnormalities in survivors of LGG at a mean of 12 years after first diagnosis.
METHODS: Patients who have had stable disease since the first assessment were invited for follow-up cognitive assessment (letter-digit substitution test, concept shifting test, Stroop colour-word test, visual verbal learning test, memory comparison test, and categoric word fluency). Compound scores in six cognitive domains (attention, executive functioning, verbal memory, working memory, psychomotor functioning, and information processing speed) were calculated to detect differences between patients who had radiotherapy and patients who did not have radiotherapy. White-matter hyperintensities and global cortical atrophy were rated on MRI scans.
FINDINGS: 65 patients completed neuropsychological follow-up at a mean of 12 years (range 6-28 years). 32 (49%) patients had received radiotherapy (three had fraction doses >2 Gy). The patients who had radiotherapy had more deficits that affected attentional functioning at the second follow-up, regardless of fraction dose, than those who did not have radiotherapy (-1.6 [SD 2.4] vs -0.1 [1.3], p=0.003; mean difference 1.4, 95% CI 0.5-2.4). The patients who had radiotherapy also did worse in measures of executive functioning (-2.0 [3.7] vs -0.5 [1.2], p=0.03; mean difference 1.5, 0.2-2.9) and information processing speed (-2.0 [3.7] vs -0.6 [1.5], p=0.05; mean difference 0.8, 0.009-1.6]) between the two assessments. Furthermore, attentional functioning deteriorated significantly between the first and second assessments in patients who had radiotherapy (p=0.25). In total, 17 (53%) patients who had radiotherapy developed cognitive disabilities deficits in at least five of 18 neuropsychological test parameters compared with four (27%) patients who were radiotherapy naive. White-matter hyperintensities and global cortical atrophy were associated with worse cognitive functioning in several domains.
INTERPRETATION: Long-term survivors of LGG who did not have radiotherapy had stable radiological and cognitive status. By contrast, patients with low-grade glioma who received radiotherapy showed a progressive decline in attentional functioning, even those who received fraction doses that are regarded as safe (</=2 Gy). These cognitive deficits are associated with radiological abnormalities. Our results suggest that the risk of long-term cognitive and radiological compromise that is associated with radiotherapy should be considered when treatment is planned. FUNDING: Kaptein Fonds; Schering Plough.

Entities:  

Mesh:

Year:  2009        PMID: 19665931     DOI: 10.1016/S1474-4422(09)70204-2

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  218 in total

1.  Initial treatment patterns over time for anaplastic oligodendroglial tumors.

Authors:  Katherine S Panageas; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán Urgoiti; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M Deangelis; Suresh C Jhanwar; Marc K Rosenblum; Andrew B Lassman
Journal:  Neuro Oncol       Date:  2012-05-31       Impact factor: 12.300

2.  Defining the optimal window for cranial transplantation of human induced pluripotent stem cell-derived cells to ameliorate radiation-induced cognitive impairment.

Authors:  Munjal M Acharya; Vahan Martirosian; Lori-Ann Christie; Lara Riparip; Jan Strnadel; Vipan K Parihar; Charles L Limoli
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

Review 3.  [Neurological complications of neurooncological therapy].

Authors:  U Herrlinger; J P Steinbach
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

4.  Cognitive functioning in newly presenting patients with supratentorial intracranial tumors: is there a role for inspection time?

Authors:  Jennifer L Scotland; Ian R Whittle; Ian J Deary
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

Review 5.  Review on quality of life issues in patients with primary brain tumors.

Authors:  Martin J B Taphoorn; Eefje M Sizoo; Andrew Bottomley
Journal:  Oncologist       Date:  2010-05-27

Review 6.  Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.

Authors:  Dina Randazzo; Katherine B Peters
Journal:  CNS Oncol       Date:  2016-07-11

Review 7.  Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities.

Authors:  Martin Klein
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

8.  Stereotactic iodine-125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region.

Authors:  Maximilian I Ruge; Philipp Kickingereder; Stefan Grau; Franziska Dorn; Norbert Galldiks; Harald Treuer; Volker Sturm
Journal:  Neuro Oncol       Date:  2013-09-17       Impact factor: 12.300

9.  Risk for unemployment at 10 years following cancer diagnosis among very long-term survivors: a population based study.

Authors:  Yakir Rottenberg; Angela G E M de Boer
Journal:  J Cancer Surviv       Date:  2020-02-14       Impact factor: 4.442

10.  Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.

Authors:  Michael Wahl; Joanna J Phillips; Annette M Molinaro; Yi Lin; Arie Perry; Daphne A Haas-Kogan; Joseph F Costello; Manisha Dayal; Nicholas Butowski; Jennifer L Clarke; Michael Prados; Sarah Nelson; Mitchel S Berger; Susan M Chang
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.